[1] World Health Organization. World cancer report 2008[M]. World Health Organization, 2008
[2] Kresge C T, Leonowicz M E, Roth W J, et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism[J]. Nature, 1992, 359(6 397): 710-712
[3] Vallet-Regi M, Ramila A, Del Real R P, et al. A new property of MCM-41: Drug delivery system[J]. Chemistry of Materials, 2001, 13(2): 308-311
[4] Tang F, Li L, Chen D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery[J]. Advanced Materials, 2012, 24(12): 1 504-1 534
[5] Hudson S P, Padera R F, Langer R, et al. The biocompatibility of mesoporous silicates[J]. Biomaterials, 2008, 29(30): 4 045-4 055
[6] 张阳德. 纳米生物技术学[M]. 北京: 科学出版社, 2005 Zhang Yangde. Nano biological technology[M]. Beijing: Science Press, 2005(in Chinese)
[7] Liu J, Yang H, Kleitz F, et al. Yolk-Shell hybrid materials with a periodic mesoporous organosilica shell: Ideal nanoreactors for selective alcohol oxidation[J]. Advanced Functional Materials, 2012, 22(3): 591-599
[8] Such G K, Johnston A P R, Caruso F. Engineered hydrogen-bonded polymer multilayers: From assembly to biomedical applications[J]. Chemical Society Reviews, 2011, 40(1): 19-29
[9] Fang Y, Zheng G, Yang J, et al. Dual-Pore mesoporous carbon@silica composite core-shell nanospheres for multidrug delivery[J]. Angewandte Chemie, 2014, 126(21): 5 470-5 474
[10] Wang G, Otuonye A N, Blair E A, et al. Functionalized mesoporous materials for adsorption and release of different drug molecules: A comparative study[J]. Journal of Solid State Chemistry, 2009, 182(7): 1 649-1 660
[11] He Q, Ma M, Wei C, et al. Mesoporous carbon@ silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging[J]. Biomaterials, 2012, 33(17): 4 392-4 402
[12] Yang P, Gai S, Lin J. Functionalized mesoporous silica materials for controlled drug delivery[J]. Chemical Society Reviews, 2012, 41(9): 3 679-3 698
[13] Izquierdo-Barba I, Martinez Á, Doadrio A L, et al. Release evaluation of drugs from ordered three-dimensional silica structures[J]. European Journal of Pharmaceutical Sciences, 2005, 26(5): 365-373
[14] Izquierdo-Barba I, Sousa E, Doadrio J C, et al. Influence of mesoporous structure type on the controlled delivery of drugs: Release of ibuprofen from MCM-48, SBA-15 and functionalized SBA-15[J]. Journal of Sol-Gel Science and Technology, 2009, 50(3): 421-429
[15] Vallet-Regí M, Balas F, Colilla M, et al. Bone-Regenerative bioceramic implants with drug and protein controlled delivery capability[J]. Progress in Solid State Chemistry, 2008, 36(3): 163-191
[16] Rosenholm J M, Lindén M. Towards establishing structure activity relationships for mesoporous silica in drug delivery applications[J]. Journal of Controlled Release, 2008, 128(2): 157-164
[17] Wang G, Otuonye A N, Blair E A, et al. Functionalized mesoporous materials for adsorption and release of different drug molecules: A comparative study[J]. Journal of Solid State Chemistry, 2009, 182(7): 1 649-1 660
[18] Rosenholm J M, Lindén M. Wet-Chemical analysis of surface concentration of accessible groups on different amino-functionalized mesoporous SBA-15 silicas[J]. Chemistry of Materials, 2007, 19(20): 5 023-5 034
[19] Suzuki T M, Nakamura T, Fukumoto K, et al. Direct synthesis of amino-functionalized monodispersed mesoporous silica spheres and their catalytic activity for nitroaldol condensation[J]. Journal of Molecular Catalysis A: Chemical, 2008, 280(1): 224-232
[20] Costa P, Lobo J M S. Modeling and comparison of dissolution profiles[J]. European Journal of Pharmaceutical Sciences, 2001, 13(2): 123-133
[21] 高立军, 王维贤, 梅兴国. 盐酸非索非那定片溶出度测定方法的研究[J]. 科学技术与工程, 2004 (11): 977-978 Gao Lijun, Wang Weixian, Mei Xingguo. Study on determination method of dissolution of Fexofenadine hydrochloride[J]. Science Technology and Engineering, 2004(11): 977-978 (in Chinese)
[22] Yuan Z, Liu S, Chen T, et al. Synthesis of iron-containing MCM-41[J]. Journal of the Chemical Society-Chemical Communications, 1995 (2): 973-974
[23] Yang P, Quan Z, Lu L, et al. Bioactive, luminescent and mesoporous europium-doped hydroxyapatite as a drug carrier[J]. Biomaterials,2008, 29: 4 341-4 347
[24] Maria C A S, Zhao X. Functionalization of SBA-15 with APTES and characterization of functionalized materials[J]. The Journal of Physical Chemistry B, 2003, 107(46): 12 650-12 657
[25] 林健. 催化剂对正硅酸乙酯水解-聚合机理的影响[J]. 无机材料学报, 1997, 12(3): 363-369 Lin Jian. Effects of catalyst on TEOS hydrolysis-polymerization mechanism[J]. Journal of Inorganic Materials, 1997, 12 (3): 363-369 (in Chinese)
[26] 陈仲冬. 双表面活性剂模板法制备介孔二氧化硅及其应用研究[D]. 杭州: 浙江大学, 2012 Chen Zhongdong. Mesoporous silica nanoparticles synthesized by binary surfactant templating system and their applications[D]. Hangzhou: Zhejiang University, 2012 (in Chinese)
[27] Munoz B, Ramila A, Perez-Pariente J, et al. MCM-41 organic modification as drug delivery rate regulator[J]. Chemistry of Materials, 2003, 15(2): 500-503